# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-02-06
**æ›´æ–°æ—¶é—´**: 2026-02-07 04:07
**æ–°é—»æ•°é‡**: 105

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šç„¦ç‚¹é›†ä¸­åœ¨GLP-1è¯ç‰©å¸‚åœºçš„æ¿€çƒˆç«äº‰ä¸ç›‘ç®¡å†²çªï¼Œä»¥åŠç”Ÿç‰©ç§‘æŠ€IPOå¸‚åœºçš„æ˜¾è‘—å¤è‹ã€‚FDAå±€é•¿å…¬å¼€è­¦å‘Šå°†æ‰“å‡»Hims & Hersç­‰å…¬å¸å¯¹Wegovyä»¿åˆ¶ç‰ˆçš„å¤§è§„æ¨¡è¥é”€ï¼Œå¼•å‘è¡Œä¸šå¯¹åˆè§„é£é™©çš„å…³æ³¨ã€‚åŒæ—¶ï¼Œå¤šå®¶AIé©±åŠ¨å’Œç”Ÿç‰©ç§‘æŠ€å…¬å¸æˆåŠŸè¿›è¡ŒIPOï¼Œæ˜¾ç¤ºèµ„æœ¬å¸‚åœºå¯¹åˆ›æ–°ç–—æ³•çš„ä¿¡å¿ƒå›æš–ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**2. FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push** â­â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - FDAå±€é•¿å…¬å¼€è¡¨æ€å°†ä¸¥å‰æ‰“å‡»GLP-1è¯ç‰©ä»¿åˆ¶ç‰ˆçš„å¤§è§„æ¨¡è¥é”€ï¼Œç›´æ¥å½±å“å‡è‚¥è¯å¸‚åœºç«äº‰æ ¼å±€ä¸åˆè§„ç¯å¢ƒã€‚

**13. Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - Hims & Hersæ¨å‡ºä½ä»·Wegovyä»¿åˆ¶ç‰ˆå¼•å‘è¯ºå’Œè¯ºå¾·æ³•å¾‹å¨èƒï¼Œå‡¸æ˜¾GLP-1å¸‚åœºå®šä»·æˆ˜ä¸çŸ¥è¯†äº§æƒå†²çªã€‚

**1. Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - AIç”Ÿç‰©æŠ€æœ¯é¢†å†›ä¼ä¸šåœ¨IIIæœŸè¯•éªŒå¯åŠ¨åè¿…é€Ÿç”³è¯·IPOï¼Œåæ˜ èµ„æœ¬å¸‚åœºå¯¹AIé©±åŠ¨è¯ç‰©ç ”å‘çš„é«˜åº¦å…³æ³¨ã€‚

**25. Agomab, SpyGlass cap biggest week for biotech IPOs since 2021** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - ç”Ÿç‰©ç§‘æŠ€IPOè¿æ¥è‡ª2021å¹´ä»¥æ¥æœ€æ´»è·ƒçš„ä¸€å‘¨ï¼Œæ˜¾ç¤ºè¡Œä¸šèèµ„ç¯å¢ƒæ˜¾è‘—æ”¹å–„ã€‚

**4. FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill** â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - æ”¿åºœèµ„åŠ©æ³•æ¡ˆé‡æ–°æˆæƒç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’ï¼Œå°†åŠ é€Ÿå„¿ç«¥ç½•è§ç—…è¯ç‰©å¼€å‘ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): AIé©±åŠ¨è¯ç‰©ç ”å‘å…¬å¸Generate:Biomedicinesæ¨è¿›ç®¡çº¿ï¼›å®‰æ–¯æ³°æ¥æŠ—ç™Œè¯Vyloyé”€å”®è¶…é¢„æœŸï¼›BMSå’ŒGSKå¼ºè°ƒä»¥äº§å“ä¸ºæ ¸å¿ƒçš„ç ”å‘ç­–ç•¥ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): Generate:Biomedicinesåœ¨IIIæœŸè¯•éªŒç»™è¯åè¿…é€Ÿç”³è¯·IPOï¼›BMSè¿‘æœŸå°†æœ‰è‡³å°‘10é¡¹å…³é”®ä¸´åºŠæ•°æ®è¯»å‡ºï¼ŒææŒ¯ç®¡çº¿ä¿¡å¿ƒã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

é‡ç‚¹å…³æ³¨FDAå¯¹Hims & Herså¤åˆç‰ˆWegovyçš„ç›‘ç®¡è¡ŒåŠ¨è¿›å±•ï¼Œä»¥åŠè¯ºå’Œè¯ºå¾·å¯èƒ½é‡‡å–çš„æ³•å¾‹æªæ–½ï¼›åŒæ—¶ç•™æ„ç”Ÿç‰©ç§‘æŠ€IPOå¸‚åœºçš„åç»­è¡¨ç°ï¼Œç‰¹åˆ«æ˜¯Generate:Biomedicinesç­‰å…¬å¸çš„ä¸Šå¸‚åè‚¡ä»·èµ°åŠ¿ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç»¼åˆ (ç»¼åˆ) | 42 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 9 |

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 12:00
- **é‡è¦æ€§**: â­â­â­â­â­

> Just nine days after dosing the first patient in a Phase 3 trial, Generate:Biomedicines has filed for an IPO. The Flagship Pioneering-backed startup has become a richly-funded leader of AI bio since its founding in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/)

---

### ğŸ‡ºğŸ‡¸ Orphan drug tweak in US spending bill will make life easier for the FDA

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 19:10
- **é‡è¦æ€§**: â­â­â­â­

> The FDA can continue to grant seven years of exclusivity for orphan drugs with new indications, as President Donald Trump this week signed a government funding extension that included a provision that codifies that process ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/orphan-drug-tweak-in-us-spending-bill-will-make-life-easier-for-the-fda/)

---

### ğŸ‡ºğŸ‡¸ Eikon IPO analysis: Big biotech names, big valuation cut

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 14:32
- **é‡è¦æ€§**: â­â­â­â­

> For Eikon Therapeutics, its IPO feels more like something itâ€™s surviving rather than celebrating. The Bay Area startup is one of biotechâ€™s most prominent privately-held companies, after raising more than $1 billion to advance its ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/)

---

### ğŸ‡ºğŸ‡¸ Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 15:22
- **é‡è¦æ€§**: â­â­â­

> Thermo Fisher Scientific is closing its chemical analysis manufacturing site in Franklin, MA, due to â€œcurrent customer demands,â€ a company spokesperson told Endpoints News. Operations there will be phased out by the end of the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/thermo-fisher-charles-river-workforce-cuts-wuxi-signs-contract-with-vertex/)

---

### ğŸ‡ºğŸ‡¸ Agomab, SpyGlass bank a combined $350M in biotech IPOs

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-06 00:59
- **é‡è¦æ€§**: â­â­

> The two offerings capped off the busiest week for new biotech stock issuances in a year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/agomab-spyglass-biotech-ipo-price-2026/811385/)

---

### ğŸ‡ºğŸ‡¸ Novo, Lilly sputter as Hims launches knockoff GLP-1 pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 17:22
- **é‡è¦æ€§**: â­â­

> Novo is threatening litigation in response, while FDA head Martin Makary, without naming specific companies, said the agency would take &ldquo;swift action&rdquo; against those &ldquo;mass-marketing illegal copycat drugs.&rdquo;&nbsp;&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/hims-compounded-wegovy-glp-1-obesity-novo-lilly/811476/)

---

### ğŸ‡ºğŸ‡¸ Generate, an AI-driven Flagship startup, pitches an IPO

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 16:32
- **é‡è¦æ€§**: â­â­

> The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/generate-biomedicines-ipo-flagship-ai-tlsp/811482/)

---

### ğŸ‡ºğŸ‡¸ Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 01:08
- **é‡è¦æ€§**: â­â­

> The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/eikon-biotech-ipo-price-cancer-drugs-2026/811169/)

---

### ğŸ‡ºğŸ‡¸ Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 17:18
- **é‡è¦æ€§**: â­â­

> The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/trump-signs-legislation-end-partial-government-shutdown-pbm-reform-telehealth-hospital-at-home/811365/)

---

### ğŸ‡ºğŸ‡¸ Agomab, SpyGlass cap biggest week for biotech IPOs since 2021

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 16:26
- **é‡è¦æ€§**: â­â­

> Biotech IPOs are on the comeback trail. Fibrosis-focused Agomab Therapeutics and eye disease company SpyGlass Pharma will go public on Friday in respective $200 million and

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/agomab-spyglass-cap-biggest-week-for-biotech-ipos-since-2021/)

---

### ğŸ‡ºğŸ‡¸ Illumina bets on healthcare after Trump administration's NIH funding disruptions

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 09:19
- **é‡è¦æ€§**: â­â­

> DNA sequencing company Illumina is leaning more into healthcare after its traditional research market was rattled by the Trump administration's disruptions to NIH funding. After a string of largely ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/illumina-bets-on-healthcare-after-trump-administrations-nih-funding-disruptions/)

---

### ğŸ‡ºğŸ‡¸ FDA chief Makary takes aim at Hims' compounded Wegovy pill plans

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 23:52
- **é‡è¦æ€§**: â­â­

> FDA Commissioner Marty Makary took a not-so-subtle swipe at Hims &amp; Hers in a social media post Thursday, saying his agency would "take swift action against companies mass-marketing illegal copycat drugs." Without naming Hims, Makary' ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-chief-makary-takes-aim-at-hims-compounded-wegovy-pill-plans/)

---

### ğŸ‡ºğŸ‡¸ Veradermics CEO has a great hair day with 122% pop in IPO

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 18:34
- **é‡è¦æ€§**: â­â­

> Investors are showing some love to the biotech testing an oral form of Rogaine, betting that people will want good hair too as the aesthetics market surges with direct-to-consumer GLP-1s. Veradermics' stock surged 122% in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/veradermics-ceo-has-a-great-hair-day-with-122-pop-in-ipo/)

---

### ğŸ‡ºğŸ‡¸ Bristol Myers draws pipeline excitement as several data readouts near

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 15:50
- **é‡è¦æ€§**: â­â­

> For the first time in a while, investors seem excited about Bristol Myers Squibbâ€™s late-stage pipeline. Bristol Myers on Thursday flagged at least 10 potential data readouts coming this year that could lead to new ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/bristol-myers-draws-pipeline-excitement-as-several-data-readouts-near/)

---

### ğŸ‡ºğŸ‡¸ Telehealth provider Hims goes after Novo's weight loss pill with compounded version

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 14:58
- **é‡è¦æ€§**: â­â­

> Online healthcare provider Hims &amp; Hers said it would start selling a compounded version of Novo Nordiskâ€™s Wegovy pill on Thursday, just a month after the FDAâ€™s approval of the brand-name pill version of the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/telehealth-provider-hims-goes-after-novos-weight-loss-pill-with-compounded-version/)

---

### ğŸ‡ºğŸ‡¸ Eisai gains Henlius therapy; LB Pharma snags $100M in funding

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 14:21
- **é‡è¦æ€§**: â­â­

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eisai-gains-henlius-therapy-lb-pharma-snags-100m-in-funding/)

---

### ğŸ‡ºğŸ‡¸ Bayer details anticipated stroke prevention data for new blood-thinner

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 17:15
- **é‡è¦æ€§**: â­

> Asundexian&nbsp;cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/bayer-asundexian-factorXIa-secondary-stroke-data-conference/811455/)

---

### ğŸ‡ºğŸ‡¸ Geoff McDonough's big plans for NodThera's NLRP3; Enhertu leader steps down at Daiichi

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 12:00
- **é‡è¦æ€§**: â­

> Geoff McDonough is tipping his hat to one of the hottest targets in drug development right now. The former Generation Bio CEO has joined NodThera to get its NLRP3 program into Phase 3 next year ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/geoff-mcdonoughs-big-plans-for-nodtheras-nlrp3-enhertu-leader-steps-down-at-daiichi/)

---

### ğŸ‡ºğŸ‡¸ Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 12:00
- **é‡è¦æ€§**: â­

> Priovant Therapeutics, a Roivant spinout, announced that an experimental immune drug it inherited from Pfizer succeeded in a Phase 2 trial for cutaneous sarcoidosis, a rare condition that causes small bumps or ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/)

---

### ğŸ‡ºğŸ‡¸ #ISC26: Bayerâ€™s asundexian reduced ischemic strokes by 26% in Phase 3 trial

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 17:15
- **é‡è¦æ€§**: â­

> Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/isc26-bayers-asundexian-reduced-ischemic-strokes-by-26-in-phase-3-trial/)

---

### ğŸ‡ºğŸ‡¸ Angitia gets $130M Series D for pipeline of musculoskeletal drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 12:30
- **é‡è¦æ€§**: â­

> A US-China biotech has reeled in $130 million for three biologics in clinical testing for musculoskeletal diseases, including one in which Ultragenyx recently came up short. Angitia Biopharmaceuticals disclosed its Series D ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/)

---

### ğŸ‡ºğŸ‡¸ White Houseâ€™s online service for drug sales debuts with limited impact on prices

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-06 17:08

> Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won&rsquo;t be felt by many Americans whose medications are covered by insurance.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/trump-rx-drug-prices-discount-white-house/811576/)

---

### ğŸ‡ºğŸ‡¸ Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myersâ€™ waiting game

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 21:32

> Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/bristol-myers-abbvie-gsk-vaccines-biotech-earnings-q4-2025/811463/)

---

### ğŸ‡ºğŸ‡¸ Express Scripts reaches â€˜landmarkâ€™ settlement with FTC in insulin suit

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 11:46

> The agreement announced Wednesday includes sweeping changes to the Cigna PBM&rsquo;s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/express-scripts-ftc-reach-settlement-insulin-lawsuit/811436/)

---

### ğŸ‡ºğŸ‡¸ Novo shares tumble by double digits on grim sales outlook

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 16:55

> In contrast to Lilly&rsquo;s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/novo-nordisk-2025-earnings-2026-outlook/811318/)

---

### ğŸ‡ºğŸ‡¸ US calls for DOJ investigation of Hims over GLP-1 drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 23:08

> The US government said it will refer telehealth and GLP-1 company Hims &amp; Hers to the Department of Justice for investigation, following the company's controversial launch of a compounded version of Novo ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/)

---

### ğŸ‡ºğŸ‡¸ TrumpRx launch falls flat for some, citing generic access

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 21:01

> When President Donald Trump unveiled his anticipated direct-to-consumer drug platform on Thursday, he said he'd done what other politicians had promised but never delivered. "They all failed,â€ he said. â€œIt was all words as usual" ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/trumprx-launch-falls-flat-for-some-citing-generic-access/)

---

### ğŸ‡ºğŸ‡¸ HHS drops legal fight over blocked 340B rebate pilot

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 19:19

> The Trump administration is taking a step back from its planned 340B rebate pilot that a court blocked last month. HHS asked a Maine federal court to set aside actions related to the original pilot ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/hhs-drops-legal-fight-over-blocked-340b-rebate-pilot/)

---

### ğŸ‡ºğŸ‡¸ Biogen CEO says Alzheimer's drug Leqembi on track for continued growth

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 16:11

> Biogen and Eisai's Alzheimerâ€™s drug Leqembi appears to have reached some stable growth after a bumpy couple of years. Leqembi generated $134 million in fourth-quarter sales worldwide in 2025, jumping 54% from the previous year ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/biogen-ceo-says-alzheimers-drug-leqembi-on-track-for-continued-growth/)

---

### ğŸ‡ºğŸ‡¸ UniQure pauses higher doses in Fabry study; Aro shares Pompe data

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 15:00

> â¸ï¸ UniQure pauses mid- and high-doses in Fabry gene therapy study: The company reported that two patients who received a 4x1013 genome copies per kilogram (gc/kg) dose faced grade 3 liver enzyme elevations. That comes ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/uniqure-pauses-higher-doses-in-fabry-study-aro-shares-pompe-data/)

---

### ğŸ‡ºğŸ‡¸ Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-06 12:00

> I've been waiting for the big showdown between drugmakers and compounders for months, and it's finally here. Today on Post-Hoc Live at 12 p.m. ET, we'll be talking about telehealth company Hims &amp; Hers' plan ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/)

---

### ğŸ‡ºğŸ‡¸ Novo's threat to sue Hims over Wegovy pill faces legal hurdle

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 21:25

> Novo Nordisk's threatened legal action against Hims &amp; Hers for selling a compounded version of the pharma giantâ€™s newly launched Wegovy pill may be far from a slam-dunk win. Dae Lee, an attorney at Buchanan ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novos-threat-to-sue-hims-over-wegovy-pill-faces-legal-hurdle/)

---

### ğŸ‡ºğŸ‡¸ White House launches TrumpRx

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 20:55

> The White House on Thursday launched TrumpRx, the long-awaited direct-to-consumer hub that's a cornerstone of the administrationâ€™s push to lower drug prices. The official unveiling had been months in the making and was slightly delayed ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/white-house-plans-to-launch-trumprx-thursday/)

---

### ğŸ‡ºğŸ‡¸ GLP-1s and the Super Bowl

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-05 15:41

> The Super Bowl is once again getting the GLP-1 ad treatment. Hims &amp; Hers is back with another combative spot that calls out the disparities in healthcare experiences between the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/glp-1s-and-the-super-bowl/)

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ UPDATE: FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-06 09:47
- **é‡è¦æ€§**: â­â­â­â­

> â€œFDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,â€ FDA commissioner Marty Makary, M.D., said in a Feb. 5 post on X. The comments mark a clear and sharp rebuttal to Himsâ€™ announcement earlier in the day that it had launched a compounded version of Novo Nordiskâ€™s new Wegovy pill for obesity, just weeks after Novo's own launch.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/after-hims-compounded-wegovy-pill-upset-fdas-makary-pledges-crackdown-mass-marketing-illegal)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”Amgen, Kyowa's OX40 divorce; Roche's RNAi deal; Daiichi's ADC cull

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 15:16
- **é‡è¦æ€§**: â­â­â­â­

> Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche penned a deal worth up to $1.7 billion for an RNA interference program from SanegeneBio. Daiichi Sankyo stopped development of its first non-DXd candidate. And more.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/amgen-kyowa-ox40-divorce-roche-rnai-deal-daiichi-adc-cull)

---

### ğŸ‡ºğŸ‡¸ FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 15:02
- **é‡è¦æ€§**: â­â­â­â­

> By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill)

---

### ğŸ‡ºğŸ‡¸ STAT+: HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-07 01:05
- **é‡è¦æ€§**: â­â­â­â­

> FDA will take â€œdecisive stepsâ€ to thwart companies from mass marketing unapproved, compounded versions of GLP-1 drugs

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/06/fda-take-action-against-hims-telehealth-wegovy-compounding/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Novo adds star-studded first Super Bowl spot to Wegovy pillâ€™s â€˜dramaticâ€™ rollout blitz

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 15:57
- **é‡è¦æ€§**: â­â­

> Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertisingâ€™s biggest stage to help get the word out.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/novo-adds-star-studded-first-super-bowl-ad-wegovy-pills-dramatic-rollout-blitz)

---

### ğŸ‡ºğŸ‡¸ Him &amp; Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 12:20
- **é‡è¦æ€§**: â­â­

> A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims &amp; Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/health-tech/him-hers-plans-offer-cheaper-version-wegovy-pill-prompting-novo-nordisk-threaten-legal)

---

### ğŸ‡ºğŸ‡¸ With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 11:16
- **é‡è¦æ€§**: â­â­

> The majority of Bristol Myers Squibb's $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/stagnating-sales-older-legacy-meds-bms-leans-new-growth-drivers-weather-storm)

---

### ğŸ‡ºğŸ‡¸ Astellas tops expectations as Vyloy sales surge outshines trial setback

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 10:31
- **é‡è¦æ€§**: â­â­

> Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/astellas-tops-expectations-vyloy-sales-surge-outshines-trial-setback)

---

### ğŸ‡ºğŸ‡¸ A cut above: Veradermics locks in $256M IPO and shares spike

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 09:43
- **é‡è¦æ€§**: â­â­

> In its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according to a Securities and Exchange Commission filing. Veradermics is trading under the symbol "MANE."

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/cut-above-hair-regrowth-biotech-veradermics-locks-oversubscribed-256m-ipo)

---

### ğŸ‡ºğŸ‡¸ Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:27
- **é‡è¦æ€§**: â­â­

> Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company's momentum is such that it still expects revenues to reach between $80 billion and $83 billion, which would be a 25% increase from 2025 sales at the midpoint.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026)

---

### ğŸ‡ºğŸ‡¸ AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&amp;J competition

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:08
- **é‡è¦æ€§**: â­â­

> AbbVie's immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company's yearly haul of $61.1 billion.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj)

---

### ğŸ‡ºğŸ‡¸ As CEO, Luke Miels wants GSK to be more 'product-centric'

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 09:10
- **é‡è¦æ€§**: â­â­

> In his first investor update as GSKâ€™s CEO, Luke Miels defined a core of his vision for the companyâ€™s next chapter: â€œWe need to be more product-centric as a company.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/ceo-luke-miels-wants-gsk-be-more-product-centric)

---

### ğŸ‡ºğŸ‡¸ STAT+: IPOs, GLP-1s, and challenges with a gene therapy

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-06 14:19
- **é‡è¦æ€§**: â­â­

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/06/biotech-news-trumprx-launches-and-roivant-scores-a-win/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 14:25
- **é‡è¦æ€§**: â­â­

> Based on ads released in advance of the Super Bowl, little has changed in the eyes of the pharma industry since the FDA began a "crackdown" on drug marketing

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/05/fda-ftc-pbm-super-bowl-teva-autism-layoffs-vertex-amgen/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ The FDA wants to rein in drug ads. On Super Bowl Sunday, it will be business as usual

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 09:30
- **é‡è¦æ€§**: â­â­

> On Super Bowl Sunday, the drug industry is trotting out lounging football stars, a shouting DJ Khaled, and the soothing tones of Enya.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/drug-ads-super-bowl-sunday-fda/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about worries over FDA voucher program, a new U.S. Novo exec, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 14:09
- **é‡è¦æ€§**: â­â­

> FDA leaders tried to quell concerns about a controversial new program to fast-track certain drugs at an employee town hall meeting

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/04/novo-obesity-trump-psychedelics-fda-vouchers-switzerland/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:28
- **é‡è¦æ€§**: â­â­

> Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 11:20
- **é‡è¦æ€§**: â­

> Bristol Myers Squibb has signed Kasey Keller for a Breyanzi partnership, giving the U.S, Soccer Hall of Famer a platform to discuss how the CD19-directed CAR-T cell therapy blocked the recurrence of his non-Hodgkin lymphoma.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bristol-myers-celebrates-us-soccer-legends-shutout-against-cancer-breyanzi-ad)

---

### ğŸ‡ºğŸ‡¸ OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 09:47
- **é‡è¦æ€§**: â­

> OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giantâ€™s CAR-T programs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/oxb-expands-bms-partnership-churn-out-lentiviral-vectors-car-t)

---

### ğŸ‡ºğŸ‡¸ Lilly likens relentless work of scientific and athletic progress in Winter Olympics ad

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-06 12:26

> As the 2026 Winter Olympics get underway in Italy this week, Eli Lillyâ€”a partner of both Team USA and the Milan Cortina Games as a wholeâ€”is rolling out a new corporate campaign inspired by the event.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/lilly-likens-relentless-work-scientific-and-athletic-progress-ad-timed-winter-olympics)

---

### ğŸ‡ºğŸ‡¸ Rocheâ€™s Genentech cut at least 489 jobs last year, new disclosure reveals

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-06 13:23

> On top of 348 known job cuts across the organization last year, Genentech laid off an additional 141 staffers last August that are just now being disclosed.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/genentech-cut-least-489-jobs-last-year-new-disclosure-reveals)

---

### ğŸ‡ºğŸ‡¸ Biogen pins SMA recovery on high-dose Spinraza amid projected 2026 revenue slump

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-06 11:32

> Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose version of the spinal muscular atrophy treatment in Japan.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/biogen-counting-upcoming-fda-decision-hd-spinraza-reverse-sales-slide)

---

### ğŸ‡ºğŸ‡¸ BridgeBio shares slide as Pfizer's tafamidis patent revoked in Europe

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-06 10:10

> The stock price of BridgeBio plunged 15% Thursday on Pfizer's reported decision to withdraw a tafamidis patent in the EU, triggering fears of earlier generic entry in the blockbuster ATTR-CM market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/bridgebio-shares-slide-amid-pfizer-reported-decision-withdraw-vyndamax-eu-patent)

---

### ğŸ‡ºğŸ‡¸ The biggest potential drug launches of 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 15:34

> On this weekâ€™s "The Top Line," Fierceâ€™s Andrea Park and Gabrielle Masson dive into the most anticipated drug launches of 2026 and the blockbuster sales potential shaping biopharmaâ€™s next wave.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/biggest-potential-drug-launches-2026)

---

### ğŸ‡ºğŸ‡¸ UPDATE: TrumpRx, US government's cash-pay drug purchasing portal, has arrived

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 14:31

> Thursday evening, President Donald Trump debuted TrumpRx, a government-run website that directs patients toward cash-pay channels where they can purchase certain prescription drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trumprx-governments-cash-pay-drug-purchasing-tool-primed-launch)

---

### ğŸ‡ºğŸ‡¸ Merz steps into the ring with Muhammad Ali-inspired Inbrija campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-05 07:41

> Merz Therapeutics has launched a punchy marketing campaign for Parkinsonâ€™s disease drug Inbrija, working Muhammad Ali quotes and footage into a revised version of the medâ€™s â€œFor the Fightersâ€ initiative.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/merz-steps-ring-muhammad-ali-inbrija-campaign)

---

### ğŸ‡ºğŸ‡¸ Sun Pharma marks Super Bowl â€˜SUNdayâ€™ with skin cancer awareness drive

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:53

> For Sun Pharma, every dayâ€”from Super Bowl Sunday and beyondâ€”is â€œSUNday.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/sun-pharma-marks-super-bowl-sunday-skin-cancer-awareness-drive)

---

### ğŸ‡ºğŸ‡¸ Novartis CEO projects 2026 growth despite â€˜largest patent expiryâ€™ in company history

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 13:40

> Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmakerâ€™s fourth-quarter results start to show the impact of the â€œlargest patent expiryâ€ in its history.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novartis-ceo-projects-2026-growth-despite-largest-patent-expiry-company-history)

---

### ğŸ‡ºğŸ‡¸ STAT+: TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-06 22:59

> STAT analysis: Many of the prescription drugs on TrumpRx are available elsewhere as cheaper generics.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/06/trumprx-discount-drug-website-undercut-by-cheaper-generics/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: White House looks for more drug pricing deals to add to TrumpRx

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-06 18:36

> The Trump administration wants more companies to offer prescription drugs at discounted cash prices on TrumpRx.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/06/white-house-wants-more-pharma-companies-on-trumprx/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-06 16:11

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/06/pharma-biotech-jobs-astrazeneca-novo/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about TrumpRx, Hims & Hers selling compounded Wegovy pill, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-06 14:21

> President Trump on Thursday night launched TrumpRx, the website he and his aides have touted as a platform aimed at lowering drug prices

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/06/trump-hims-wegovy-novo-obesity-cvs-340b-fda/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Statins donâ€™t cause most of the side effects on package warnings, study finds

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 23:30

> Many people who should be taking statins avoid them for fear of side effects. A large new study says most of those side effects don't actually show up.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/statin-side-effects-evidence-lacking-lancet-study-says/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo Nordisk accuses Hims & Hers of â€˜illegal mass compoundingâ€™ over a cheaper version of Wegovy pill

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 20:51

> Hims &#38; Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of â€œillegal&#8230;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/05/novo-weight-obesity-wegovy-hims-compounding-telehealth/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ What to know about TrumpRx, the Trump administrationâ€™s prescription drug platform

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 18:00

> On Thursday, President Trump launched TrumpRx, the website he and his aides have touted for months as a platform aimed at lowering prescription drug prices.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/trumprx-what-to-know-drug-prices/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo and Lilly both see price cuts as helpful for long-term gain

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 14:36

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/biotech-news-novo-and-lilly-price-cuts-for-gain/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Opinion: TrumpRx has a fundamental flaw

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 09:30

> The real winners from TrumpRx are pharmaceutical manufacturers.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/trumprx-prescription-drug-costs-flaws/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Vertexâ€™s CRISPR treatment for sickle cell disease hits unexpected roadblock

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-05 09:30

> Vertex is running out of time to establish Casgevy as a transformative treatment for sickle cell.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/05/vertex-crispr-sickle-cell-treatment-casgevy-faces-rollout-bottleneck/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: FTC settles lawsuit with Express Scripts over charges it manipulated insulin prices, impeded access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 18:07

> The FTC settled a lawsuit against Express Scripts over allegations that the company artificially inflated the price of insulin and impeded access to treatment.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/04/pbm-cigna-express-scripts-ftc-insulin-settlement-rebates/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer defends data on Metsera candidate

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 14:44

> And other biotech news, brought to you by the Readout Newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/04/biotech-news-pfizer-defends-metsera-data/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 17:38

> Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer unveils data on Metsera drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:41

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ Oncology (Cancer)/Hematologic Malignancies Approval Notifications

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:46
- **é‡è¦æ€§**: â­â­â­â­

> FDA does not&nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&nbsp;Drugs@FDA&nbsp;for the latest approvals and prescribing information for specific products.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)

---

### ğŸ‡ºğŸ‡¸ List of Determinations Including Written Request

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:49
- **é‡è¦æ€§**: â­â­â­â­

> In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/list-determinations-including-written-request)

---

### ğŸ‡ºğŸ‡¸ Untitled Letters

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 20:49
- **é‡è¦æ€§**: â­â­

> These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion's untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters)

---

### ğŸ‡ºğŸ‡¸ Registered Outsourcing Facilities

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 16:42
- **é‡è¦æ€§**: â­â­

> Discover FDA's comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 15:15
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:46
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:44
- **é‡è¦æ€§**: â­â­

> The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers sho

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine)

---

### ğŸ‡ºğŸ‡¸ Cefiderocol Injection

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 17:07
- **é‡è¦æ€§**: â­â­

> Cefiderocol Injection - FDA Identified Interpretive Criteria

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/cefiderocol-injection)

---

### ğŸ‡ºğŸ‡¸ Notices of Updates

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 17:04
- **é‡è¦æ€§**: â­â­

> Webpage providing notices of updates to FDA's STIC webpages for antibacterial and antifungal drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/notices-updates)

---

### ğŸ‡ºğŸ‡¸ Newly Added Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 16:55
- **é‡è¦æ€§**: â­â­

> Guidance documents represent the FDA's current thinking on a particular subject. New guidance documents are listed here for three months.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 22:40

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots: LEROCHOL

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 18:29

> Drug Trials Snapshots: LEROCHOL

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lerochol)

---

### ğŸ‡ºğŸ‡¸ CDER Small Business and Industry Assistance (SBIA) Learn

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 17:01

> SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/cder-small-business-and-industry-assistance-sbia-learn)

---

### ğŸ‡ºğŸ‡¸ E22 General Considerations for Patient Preference Studies

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 13:11

> E22 General Considerations for Patient Preference Studies

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/e22-general-considerations-patient-preference-studies)

---

### ğŸ‡ºğŸ‡¸ Search for Regulatory References | Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-06 00:02

> Find information on drug development, applications, submissions, manufacturing &amp; quality, safety, labeling and more

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/search-regulatory-references-drugs)

---

### ğŸ‡ºğŸ‡¸ Recently Issued Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 19:30

> This page lists Recently Issued CBER and Cross-Center Guidance Documents.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ National Drug Code Directory

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 18:59

> National Drug Code Directory

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory)

---

### ğŸ‡ºğŸ‡¸ Electronic Registration and Listing Compliance Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 18:59

> Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-registration-and-listing-compliance-program)

---

### ğŸ‡ºğŸ‡¸ INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 18:28

> INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/news-events/expanded-access/informed-consent-template-individual-patient-expanded-access)

---

### ğŸ‡ºğŸ‡¸ Antibacterial Susceptibility Test Interpretive Criteria

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-05 17:02

> Antibacterial Susceptibility Test Interpretive Criteria

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:18
- **é‡è¦æ€§**: â­â­â­â­

> The US sees around 476,000 new Lyme cases every year

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/)

---

### ğŸ‡ºğŸ‡¸ Patient-centric oncology trials

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-05 11:35
- **é‡è¦æ€§**: â­â­

> Data-driven, patient-first: using insights in striving to transform cancer care

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/thought_leadership/patient-centric-oncology-trials/)

---

### ğŸ‡ºğŸ‡¸ IBSA UK&I launches Perovial for the treatment of acute Peyronieâ€™s disease

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:32
- **é‡è¦æ€§**: â­â­

> Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/)

---

### ğŸ‡ºğŸ‡¸ Guesswork to guidance

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-06 12:22

> What content do HCPs value most for their patient care?

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/thought_leadership/guesswork-to-guidance/)

---

### ğŸ‡ºğŸ‡¸ Connect more

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-05 11:42

> Redefining the future of customer relationships in biopharma

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/thought_leadership/connect-more/)

---

### ğŸ‡ºğŸ‡¸ Thomas Farrell

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-04 09:48

> NanoSyrinx has appointed Thomas Farrell as CEO and Director

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/thomas-farrell/)

---

### ğŸ‡ºğŸ‡¸ Ahmed Moussa

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-04 09:42

> Ahmed Moussa is the new Sanofi Country Lead for UK &#038; Ireland

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/ahmed-moussa/)

---

### ğŸ‡ºğŸ‡¸ Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:43

> The company will initially develop a vaccine to tackle colorectal and pancreatic cancers

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/)

---

### ğŸ‡ºğŸ‡¸ ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:08

> Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-02-07 04:07:08*